195 related articles for article (PubMed ID: 30699364)
21. CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma cells.
Wobus M; Rangwala R; Sheyn I; Hennigan R; Coila B; Lower EE; Yassin RS; Sherman LS
Appl Immunohistochem Mol Morphol; 2002 Mar; 10(1):34-9. PubMed ID: 11893033
[TBL] [Abstract][Full Text] [Related]
22. Hyaluronic acid-modified liposomal honokiol nanocarrier: Enhance anti-metastasis and antitumor efficacy against breast cancer.
Wang J; Liu D; Guan S; Zhu W; Fan L; Zhang Q; Cai D
Carbohydr Polym; 2020 May; 235():115981. PubMed ID: 32122511
[TBL] [Abstract][Full Text] [Related]
23. CD44 attenuates metastatic invasion during breast cancer progression.
Lopez JI; Camenisch TD; Stevens MV; Sands BJ; McDonald J; Schroeder JA
Cancer Res; 2005 Aug; 65(15):6755-63. PubMed ID: 16061657
[TBL] [Abstract][Full Text] [Related]
24. Enhanced anti-tumor and anti-metastasis therapy for triple negative breast cancer by CD44 receptor-targeted hybrid self-delivery micelles.
Yang Y; Long Y; Wang Y; Ren K; Li M; Zhang Z; Xiang B; He Q
Int J Pharm; 2020 Mar; 577():119085. PubMed ID: 32001290
[TBL] [Abstract][Full Text] [Related]
25. Neovasculature and circulating tumor cells dual-targeting nanoparticles for the treatment of the highly-invasive breast cancer.
Yao J; Feng J; Gao X; Wei D; Kang T; Zhu Q; Jiang T; Wei X; Chen J
Biomaterials; 2017 Jan; 113():1-17. PubMed ID: 27794222
[TBL] [Abstract][Full Text] [Related]
26. Liposomal Nanoparticles Carrying anti-IL6R Antibody to the Tumour Microenvironment Inhibit Metastasis in Two Molecular Subtypes of Breast Cancer Mouse Models.
Guo C; Chen Y; Gao W; Chang A; Ye Y; Shen W; Luo Y; Yang S; Sun P; Xiang R; Li N
Theranostics; 2017; 7(3):775-788. PubMed ID: 28255366
[TBL] [Abstract][Full Text] [Related]
27. A novel double-targeted nondrug delivery system for targeting cancer stem cells.
Qiao S; Zhao Y; Geng S; Li Y; Hou X; Liu Y; Lin FH; Yao L; Tian W
Int J Nanomedicine; 2016; 11():6667-6678. PubMed ID: 27994463
[TBL] [Abstract][Full Text] [Related]
28. Pt-Mal-LHRH, a Newly Synthesized Compound Attenuating Breast Cancer Tumor Growth and Metastasis by Targeting Overexpression of the LHRH Receptor.
Calderon LE; Keeling JK; Rollins J; Black CA; Collins K; Arnold N; Vance DE; Ndinguri MW
Bioconjug Chem; 2017 Feb; 28(2):461-470. PubMed ID: 27997127
[TBL] [Abstract][Full Text] [Related]
29. Co-delivery of paclitaxel and STAT3 siRNA by a multifunctional nanocomplex for targeted treatment of metastatic breast cancer.
Luo K; Gao Y; Yin S; Yao Y; Yu H; Wang G; Li J
Acta Biomater; 2021 Oct; 134():649-663. PubMed ID: 34289420
[TBL] [Abstract][Full Text] [Related]
30. Hydrophobic interaction mediating self-assembled nanoparticles of succinobucol suppress lung metastasis of breast cancer by inhibition of VCAM-1 expression.
Cao H; Zhang Z; Zhao S; He X; Yu H; Yin Q; Zhang Z; Gu W; Chen L; Li Y
J Control Release; 2015 May; 205():162-71. PubMed ID: 25598420
[TBL] [Abstract][Full Text] [Related]
31. Combination of a chemopreventive agent and paclitaxel in CD44-targeted hybrid nanoparticles for breast cancer treatment.
Tran BN; Nguyen HT; Kim JO; Yong CS; Nguyen CN
Arch Pharm Res; 2017 Dec; 40(12):1420-1432. PubMed ID: 29027133
[TBL] [Abstract][Full Text] [Related]
32. Redox Responsive Hyaluronic Acid Nanogels for Treating RHAMM (CD168) Over-expressive Cancer, both Primary and Metastatic Tumors.
Yang C; Li C; Zhang P; Wu W; Jiang X
Theranostics; 2017; 7(6):1719-1734. PubMed ID: 28529647
[TBL] [Abstract][Full Text] [Related]
33. Targeting intracellular MMPs efficiently inhibits tumor metastasis and angiogenesis.
Lv Y; Zhao X; Zhu L; Li S; Xiao Q; He W; Yin L
Theranostics; 2018; 8(10):2830-2845. PubMed ID: 29774078
[TBL] [Abstract][Full Text] [Related]
34. Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo.
Jian YS; Chen CW; Lin CA; Yu HP; Lin HY; Liao MY; Wu SH; Lin YF; Lai PS
Int J Nanomedicine; 2017; 12():2315-2333. PubMed ID: 28392690
[TBL] [Abstract][Full Text] [Related]
35. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
[TBL] [Abstract][Full Text] [Related]
36. CD44-Targeted Polymer-Paclitaxel Conjugates to Control the Spread and Growth of Metastatic Tumors.
Zaiden M; Rütter M; Shpirt L; Ventura Y; Feinshtein V; David A
Mol Pharm; 2018 Sep; 15(9):3690-3699. PubMed ID: 29957956
[TBL] [Abstract][Full Text] [Related]
37. Hyaluronan magnetic nanoparticle for mitoxantrone delivery toward CD44-positive cancer cells.
Sargazi A; Shiri F; Keikha S; Majd MH
Colloids Surf B Biointerfaces; 2018 Nov; 171():150-158. PubMed ID: 30025377
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of metastatic tumor growth and metastasis via targeting metastatic breast cancer by chlorotoxin-modified liposomes.
Qin C; He B; Dai W; Zhang H; Wang X; Wang J; Zhang X; Wang G; Yin L; Zhang Q
Mol Pharm; 2014 Oct; 11(10):3233-41. PubMed ID: 24559485
[TBL] [Abstract][Full Text] [Related]
39. Enhanced chemotherapeutic efficacy of the low-dose doxorubicin in breast cancer via nanoparticle delivery system crosslinked hyaluronic acid.
Wang Q; Zhong Y; Liu W; Wang Z; Gu L; Li X; Zheng J; Du H; Zhong Z; Xie F
Drug Deliv; 2019 Dec; 26(1):12-22. PubMed ID: 30691317
[TBL] [Abstract][Full Text] [Related]
40. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
